{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', '10. Female patients who have a positive pregnancy test result at screening or on Day 1', 'Prior/Concomitant Therapy', '11. Use of the following within the time period specified below:', 'IVIg within the 4 weeks (28 days) prior to randomization (Day 1)', 'Use of PE within the 4 weeks (28 days) prior to randomization (Day 1)', 'Use of rituximab within the 6 months (180 days) prior to screening', '12. Patients who have received previous treatment with complement-inhibitors', '(eg, eculizumab)', 'Prior/Concurrent Clinical Study Experience', '13. Participation in another interventional treatment study or use of any experimental therapy', 'within 30 days before initiation of study drug on Day 1 in this study or within 5 half-lives', 'of the study drug, whichever is greater', 'Additional Medical Conditions', '14. History of unexplained infections', '15. Active systemic bacterial, viral, or fungal infection within 14 days prior to study drug', 'administration on Day 1', '16. Presence of fever > 38\u00b0C (100.4\u00b0F) within 7 days prior to study drug administration on', 'Day 1', '5.3.', 'Lifestyle Considerations', 'No restrictions are required in this study.', '5.4.', 'Screen Failures', 'Screen failures are defined as patients who consent to participate in the clinical study but are not', 'subsequently randomized to a treatment group. A minimal set of screen failure information is', 'required to ensure transparent reporting of screen failure patients to meet the Consolidated', 'Standards of Reporting Trials publishing requirements and to respond to queries from regulatory', 'authorities. Minimal information includes demography, screen failure details, eligibility criteria,', 'and any serious adverse event (SAE).', 'Individuals who do not meet the criteria for participation in this study (screen failure) may be', 'rescreened once based on discussion and agreement between the Investigator and the Medical', 'Monitor.', 'A patient who experiences a gMG Clinical Deterioration or exacerbation/crisis during the', 'Screening Period will be considered a screening failure. Such patients may be rescreened with', 'Sponsor approval once they are treated and medically stable, in the opinion of the Investigator.', 'At least 28 days of clinical stability must exist prior to enrollment. The patient must meet all of', 'the inclusion criteria and none of the exclusion criteria at the time of rescreening in order to enter', 'the study.', 'Page 39 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', '6.', 'STUDY DRUG', '6.1.', 'Study Drugs Administered', 'Ravulizumab is formulated at pH 7.0 and is supplied in 30 mL single-use vials. Each vial of', 'ravulizumab contains 300 mg of ravulizumab (10 mg/mL) in 10 mM sodium phosphate, 150 mM', 'sodium chloride, 0.02% polysorbate 80, and water for injection. The comparator product is', 'formulated as a matching sterile, clear, colorless solution with the same buffer components, but', 'without active ingredient. Additional details are presented in Table 5.', 'Table 5:', 'Study Drug Administered', 'Product Name', 'Ravulizumab', 'Placebo', 'Dosage Form', 'Concentrated sterile, preservative-free', 'Sterile, preservative-free aqueous', 'aqueous solution (10 mg/mL) in', 'solution in single-use 30 mL vials', 'single-use 30 mL vials', 'Route of Administration', 'Intravenous infusion', 'Intravenous infusion', 'Dosing Instructions', 'Refer to pharmacy manual for dosing', 'Refer to pharmacy manual for dosing', 'instructions', 'instructions', 'Packaging and Labeling', 'Glass vials and stoppered with a butyl', 'Glass vials and stoppered with a butyl', 'rubber stopper with an aluminum', 'rubber stopper with an aluminum', 'overseal and a flip-off cap. Study drug', 'overseal and a flip-off cap. Study drug', 'will be supplied in kits.', 'will be supplied in kits.', 'Physical Description', 'Liquid solution practically free from', 'Liquid solution practically free from', 'particles', 'particles', 'Manufacturer', 'Alexion Pharmaceuticals, Inc. or', 'Alexion Pharmaceuticals, Inc. or', 'Contracted Manufacturing', 'Contracted Manufacturing', 'Organization', 'Organization', 'Source: product specifications', 'Study drug will be administered as indicated in Table 6.', 'During the Randomized-Controlled Period, patients in the ravulizumab or placebo treatment', 'groups will receive a weight-based loading dose of ravulizumab or placebo, respectively, on', 'Day 1 (Visit 2). At Visit 4 (Week 2), patients in the ravulizumab or placebo treatment groups', 'will receive weight-based maintenance doses or ravulizumab or placebo, respectively, q8w', 'through the completion of the Randomized-Controlled Period. After the completion of the', 'Randomized-Controlled Period, patients will enter the OLE Period.', 'After the 26-Week Randomized-Controlled Period and assessments on Day 183 (Week 26),', 'patients in the placebo group will receive a blinded loading dose of ravulizumab and patients in', 'the ravulizumab group will receive a blinded ravulizumab dose of 900 mg; the 900-mg dose was', 'chosen to ensure maintenance of complete C5 inhibition until the next scheduled maintenance', 'dose at Week 28 (Day 197). Starting at Week 28, all patients will begin open-label ravulizumab', 'maintenance doses q8w.', 'Page 40 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}